PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35388061-8	2022	We utilized a system to quantify in real-time cell-cell membrane fusion mediated by the SARS-CoV-2 surface protein, Spike, and its receptor, hACE2, to demonstrate that imatinib inhibits this process in an Abl1 and Abl2 independent manner.	Imatinib Mesylate	168-176	angiotensin converting enzyme 2	Homo sapiens	141-146	
34203261-0	2021	Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles.	Imatinib Mesylate	0-8	angiotensin converting enzyme 2	Homo sapiens	45-76	
34203261-0	2021	Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles.	Imatinib Mesylate	10-16	angiotensin converting enzyme 2	Homo sapiens	45-76	
34203261-2	2021	Here, we show that the receptor tyrosine kinase inhibitor imatinib (also known as STI571, Gleevec) can inhibit the expression of the endogenous ACE2 gene at both the transcript and protein levels.	Imatinib Mesylate	58-66	angiotensin converting enzyme 2	Homo sapiens	144-148	
35150639-0	2022	Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.	Imatinib Mesylate	0-8	angiotensin converting enzyme 2	Homo sapiens	93-97	
35150639-4	2022	By using structure-based high-throughput virtual screening and connectivity map database, followed with experimental validations, we identify imatinib, methazolamide, and harpagoside as direct enzymatic activators of ACE2.	Imatinib Mesylate	142-150	angiotensin converting enzyme 2	Homo sapiens	217-221	
35150639-5	2022	Imatinib and methazolamide remarkably improve metabolic perturbations in vivo in an ACE2-dependent manner under the insulin-resistant state and SARS-CoV-2-infected state.	Imatinib Mesylate	0-8	angiotensin converting enzyme 2	Homo sapiens	84-88	
35150639-7	2022	Taken together, our study shows that enzymatic activation of ACE2 via imatinib, methazolamide, or harpagoside may be a conceptually new strategy to treat metabolic sequelae of COVID-19.	Imatinib Mesylate	70-78	angiotensin converting enzyme 2	Homo sapiens	61-65	
33294307-10	2021	Our in silico study revealed that losartan and imatinib could probably: (1) decline SARS-CoV2 affinity to ACE2.	Imatinib Mesylate	47-55	angiotensin converting enzyme 2	Homo sapiens	106-110	
35220926-8	2022	Molecular dynamics simulations verified that imatinib interacts with RBD residues that are critical for ACE2 binding.	Imatinib Mesylate	45-53	angiotensin converting enzyme 2	Homo sapiens	104-108